

*Image Courtesy of CCRM Cells I See*

## ANNUAL REPORT 2018



Commercializing  
Living Therapies

# CONTENTS

Collaborations	2
Activities and Achievements	3
Corporate Message	4
CCRM CEO Report	4
CCRM Australia CEO Report	5
CCRM Milestones	6
CCRM Highlights	8
CCRM Australia in Focus	12
Governance	15

# COLLABORATIONS



- Members
- Affiliates
- Partners
- Industry

International Supporter



Government Supporters



## TRAINING PROGRAMS:




4

Students Attended Summer by Design Workshop



5

Industry Participants Attended Business of Regenerative Medicine Course



5

Student Mentees



Supported Training Participants Across 4 States in Australia (QLD, VIC, SA, WA)



20+

Applications into Training Programs Received

# ACTIVITIES AND ACHIEVEMENTS

## CCRM AUSTRALIA HAVE ACCOMPLISHED:



10<sup>+</sup>

Presented at Speaking Engagements



14

Events Attended



3

Participated in Regenerative Medicine International Conferences



12

Briefing Roadshows



50<sup>+</sup>

Industry Discussion Meetings



Secured

\$1.4M

AUD Funding



Evaluated

20<sup>+</sup>

Technologies



Created

4<sup>+</sup>

Jobs



Organised 3 Industry Based Research Projects



Hosted 1 International Delegation



## COMMUNICATIONS PLATFORM PERFORMANCE:



TWITTER Established Since October 2016:

- 642 followers
- 367 tweets posted
- 587 posts retweeted
- 189 mentions
- 292,422 Impressions



LINKEDIN Established Since October 2017:

- 82 followers (300% increase in followers since beginning of 2018)
- 42 updates
- 602 clicks to profile
- 19,313 impressions



WEBSITE Established Since October 2016:

- 8000+ page views
- 2000+ user visit sessions

# CORPORATE MESSAGE

## CCRM AUSTRALIA

CCRM Australia is a not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies.

CCRM Australia's focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners to address bottlenecks in the industry.

Modelled on the highly successful Centre for Commercialization of Regenerative Medicine (CCRM) based in Canada, CCRM Australia is a leader in developing and commercialising regenerative medicine, cell and gene technologies. Drawing from the organisation's expertise, industry and capital venture networks established over a five-year period, CCRM Australia is poised to take a leading role in supporting Australia's fast developing regenerative medicine sector.

## MISSION

As a member of the Global CCRM network, CCRM Australia is a partner to a leading-edge industry consortium. CCRM Australia is taking regenerative medicine from bench to bedside by treating and potentially curing some of the most devastating and costly diseases in the world today.

## VISION

Drawing from our strategic pillars established in the 5-year roadmap, we seek to encompass activities that enable, integrate, engage and internationalise the Australian regenerative medicine industry.



## CCRM CEO REPORT



*Michael May is President and Chief Executive Officer of CCRM. Michael sits on a number of Boards and advisory committees, including the Centre for the Commercialization of Antibodies and Biologics (CCAB); the Entrepreneurship Leadership Council at the University of Toronto; the TO Health! Human & Science Steering Committee; the Cell and Gene Therapy Insights, Editorial Advisory Board; the Industry Committee of the International Society for Stem Cell Research (ISSCR); and the Executive Committee, Alliance for Regenerative Medicine (ARM). He is also the Chairman of the start-up company ExCellThera Ltd.*

CCRM has experienced continued success this year, having recently secured another CAD\$15 million from the Government of Canada's Networks of Centres of Excellence program to deliver on its key strategic goals, having originally secured CAD\$15M in 2011. Previously in 2016, GE Healthcare and the Canadian government each contributed CAD\$20M (total CAD\$40M) for CCRM to build a fully-resourced, 10,000 ft<sup>2</sup> (930m<sup>2</sup>) facility to advance technologies and process development activities. CCRM also supports Canadian start-ups with its business development efforts with more than CAD\$1.8M into its portfolio companies by the end of 2017. Eighty disclosures were received and reviewed, and 17 regulatory projects were executed for external and internal clients. In 2015, CCRM launched its first company, ExCellThera, in partnership with IRICoR.

Strengthening international partnerships and enhancing operational activities for a prosperous future, CCRM will continue to engage on the international stage to build and support the global regenerative medicine ecosystem. Looking back at 2018,

CCRM is proud of its collaboration with CCRM Australia and its efforts to generate sustainable business processes in cell and gene therapy and regenerative medicine. The Australian Hub works closely with CCRM benefiting the *Launch > Scale > Attract* mission and global collaboration.

Integrating itself amongst regenerative medicine expertise, Australia has proven itself to be an excellent first hub for the CCRM model. With a strong history of stem cell and regenerative medicine research, teamed with a supportive government and substantial initiatives for research and development, it's been no surprise to see CCRM Australia's success.

With future hubs planned for other leading regenerative medicine centres around the world, CCRM is building a network to help academics and industry across the globe by removing and overcoming bottlenecks in the commercialisation of regenerative medicines.

It has been a pleasure to be involved with CCRM Australia this past year. Having participated in many activities involving CCRM and the local Australian Industry, I have gained unique insight into the innovative developments of many research institutes across Australia. Aside from being in Melbourne to attend the global 2018 ISSCR conference and with plans to return for the upcoming ISCT2019, I was able to take part in CCRM Australia's technology evaluations and industry networking event (hosted in part by the Victorian Government), working with key opinion leaders within the regenerative medicine sector.

CCRM looks forward to continuing the implementation of the successful CCRM model, adapting new hubs to our operating paradigm whilst capitalising on the strengths of each local industry. The creation of an Australian hub and its success provides a fantastic template for the development of other future hubs and we look forward to the further expansion of the CCRM network across the globe.

# CCRM AUSTRALIA CEO REPORT



*Silvio Tiziani is the CEO of CCRM Australia. Playing a key role in the establishment of CCRM Australia after securing funding from Monash University, MTP Connect, CSIRO and The Victorian Government, Silvio's skills focus on the specialised role of leading the strategic alliance with the Centre for Commercialization of Regenerative Medicine (CCRM). His extensive knowledge of the research landscape is well utilised and complemented by his networks within industry, international organisations and the state and federal government.*

The last 12 months have seen significant progress with CCRM Australia. With the endorsement of the 5-year strategic plan by the CCRM Australia Council and its subsequent approval by key stakeholders the Medical Technologies and Pharmaceuticals industry growth centre established by the Australian Government, MTPConnect, and the Department of Economic Development, Jobs, Transport and Resources (DEDJTR), we have been able to address many critical operational objectives and achieved several key milestones.

We were successful in securing a second round of funding from MTPConnect. This has allowed us to operationalise our program further, carrying out over 20 separate technology evaluations with assessments facilitated by senior CCRM officials and organising two training programs and numerous industry engagements. Alongside outstanding support from the Victorian government, the DEDJTR, CCRM Australia has been able to progress more rapidly than we would have otherwise been able.


Nurturing human capital to ensure Australians are a globally competitive regenerative medicine workforce has been a focus. This is evidenced by our support of early career researchers to attend the Summer by Design workshop hosted by University of Toronto's Medicine by Design (in partnership with CCRM and the Rotman School of Management) as well as providing internationally accomplished regenerative medicine mentors to 5 PhD students via the CCRM Australian IMNIS Regenerative Medicine International Mentoring Program with IMNIS.

Another focus for CCRM Australia is to support better use of the existing excellent life sciences infrastructure in Australia. An example this year is the launch of the Australian Alliance for Cell and Gene Therapy (AACGT) with partners, Cell Therapies Pty Ltd, St Vincent's Hospital Melbourne, and the CRC for Cell Manufacturing. The AACGT was created to facilitate an end to end solution spanning product, clinical and manufacturing development. All three of our partners have agreed to work cooperatively and collaboratively on this project for mutual benefit and we look forward to expanding our alliance further by including more partners who can contribute to our mission. Another example is the BioNano project, drawing together capabilities in biomaterial fabrication and existing infrastructure at the Melbourne Centre for Nanofabrication and CSIRO that can be marketed internationally. We are hopeful of securing additional funding to support this concept and collaborate with other research institutes to develop BioNano as Australia's contribution to CCRM's global network.

On the governance front, we have also taken significant steps towards establishing CCRM Australia as an initiative that has input and oversight from all elements of the sector. The formation of a governing member Council provides a keen board oversight by the original founding members of CCRM Australia. A stellar Scientific Advisory Board comprising of Australia's key academic and clinician researchers that are drawn from the stem cell, tissue engineering, cell manufacturing and device subsectors of the regenerative medicine ecosystem. This will allow us to communicate extensively with both academic and clinician researchers and is a key component of the CCRM operational model. The industry consortium, developing and nurturing Australia's growing regenerative medicine companies and supporting their exposure internationally, is ably overseen through an Industry Interface Committee that is representative of and keen to support Australian companies. The holistic governance framework allows for an integrative support network with each governing group able to provide representation and insight in manufacturing, research, government, industry and the clinical setting. I do thank all of these very generous people who have given their time and advice so freely and would like to give recognition to these individuals who appear in our governance section of this report (page 15).

With CCRM Australia having built the operational foundations over the past few years, we are proud of our accomplishments thus far as the first international hub of CCRM. We will continue our support to the regenerative medicine industry in Australia, being well placed to serve the sector and striving to be the preferred destination for the translation and commercialisation of regenerative medicine.

# CCRM AUSTRALIA MILESTONES



# 2018

## DECEMBER 2017

- CCRM Australia commences student intern project as part of MITI program – research into the manufacturing capabilities for regenerative medicine in Australia

## FEBRUARY 2018

- Establishment and first meeting of the CCRM Australia Council
- Establishment and first meeting of CCRM Australia's Industry Interface Committee

## APRIL 2018

- Formalisation of Scientific Advisory Board for CCRM Australia with 14 clinicians and researchers

## JUNE 2018

- CCRM Australia represented at ISSCR Conference (Melbourne, Australia)
- CCRM Australia represented at BIO the BIO International Convention (Boston, USA)
- MoU signed with Therapeutics Innovation Australia (TIA) to collaborate on a regenerative medicine database
- Victorian Government (DEDJTR) and CCRM Australia host delegates and invited industry representatives at special networking event to coincide with ISSCR conference.
- BioNano Initiative announced
- Cell Therapies collaboration with CCRM announced

## OCTOBER 2017

- CCRM Australia successful in securing additional funding in MTPConnect Grant Funding Program (Round 2).

## JANUARY 2018

- Erick Villaceran joins the Executive Team as Project Officer
- Heather Marriott joins the Executive Team as Events Coordinator and Executive Assistant
- CCRM Australia attend "Phacilitate - Cell and Gene World Conference" (Miami, USA)

## MARCH 2018

- Student Intern Project (MITI Program) is completed – BioNano Initiative conceptualised
- Presentation and technology evaluation with researchers at UNSW.
- Dr Chih Wei Teng appointed as Chief Operating Officer of CCRM Australia

## MAY 2018

- International Mentoring Program with IMNIS commences, with five pairs of mentees and mentors
- CCRM Australia and IMNIS mentees attend the national official launch event at KPMG (Melbourne) for 2018 IMNIS programs

## JULY 2018

- Australian Alliance for Cell and Gene Therapies (AACGT) announced: a joint initiative of CCRM Australia with St Vincent Hospital Melbourne, Cell Therapy and CTM CRC
- Training Program recipients, Sebastian Eggert and Jasmine Wilson, attend Summer by Design
- CCRM Australia COO at Business of Regenerative Medicine

# CCRM AUSTRALIA HIGHLIGHTS

## OCTOBER 2016

In 2016 the Medical Technologies and Pharmaceutical growth centre, MTPConnect, provided funding to 14 National Projects. CCRM Australia was announced as one of the projects, making it the first international hub of CCRM.


CCRM Australia has established a 5 year strategic plan that will support the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies in Australia, leveraging the network and expertise of CCRM in Canada.



## JULY 2017

CCRM Australia sponsored a delegation of Australians to attend the Business of Regenerative Medicine held in Toronto. Attendance allowed the delegates to gain insight into the commercial aspects of regenerative medicine on an international stage and offered opportunities to network with potential collaborators.

One participant, Dr Hsien Ern Tan, was the successful recipient of a CCRM Australia travel award to also attend the first Summer by Design Workshop, which comprehensively covered all aspects of regenerative medicine research from regulatory pathways commercialisation to collaboration. The workshop brought together researchers from Singapore, Japan, Germany, the Netherlands, Sweden and the United Kingdom, along with two members of a University of Toronto laboratory.



*The delegation of Australians attending the Business of Regenerative Medicine. Photo of Dr Lieven Huang, Dr Peter O'Neill, Dr Hsien Ern Tan, Dr Matthew Nussio and Lishia Sing.*



*Participants of the 2017 inaugural Summer by Design Workshop. Photo by Neil Ta*

## SEPTEMBER 2017

An Australia delegation with representatives of eight organisations paid a visit to Toronto, for the official opening of the new CCRM facility. The CCRM Australia delegation was warmly recognised and welcomed in official speeches at the opening and invited to connect with parliamentarians, major partners and neighbours of CCRM including GE Healthcare, JLABS Toronto, the Ontario Institute for Regenerative Medicine and MaRS.



*Silvio Tiziani, CEO of CCRM Australia, representing the Australian delegation (Photo from CCRM\_ca twitter)*



*Delegation from Australia visiting the new CCRM facility*



## OCTOBER 2017

Successful second round of funding from MTPConnect awarded CCRM Australia a provisional \$780,000 over two years, with matched funding coming from the sector. The funding will allow CCRM Australia to implement the first two years of the proposed 5 Year Strategy

Many of Australia's leading researchers, industry, service providers and advocates have come together in the largest national regenerative medicine industry-led consortium to date to support the creation of CCRM Australia and accelerate the commercialisation of regenerative technologies.



## JANUARY 2018

CCRM Australia represented at the Phacilitate Cell & Gene Therapy World hosted in Miami. Phacilitate is one of the regenerative medicine conferences sponsored by CCRM and has an emphasis on creating a network of partnerships and relationships that bring us closer to achieving the goal of improving patient care and developing commercially viable curative treatments. By attending these particular events, CCRM Australia has greater outreach and engagement with the global regenerative medicine community.



Attendees at the CCRM Sponsored event, Phacilitate Cell and Gene World Conference in Miami, USA (Photo from CCRM\_ca twitter)

## MARCH 2018

Beginning as a student project as part of the Monash Industry Team Initiative Program, CCRM Australia, working with various consortium members conceptualised the BioNano Initiative. With the project beginning back in December 2017, CCRM Australia has evaluated the regenerative medicine manufacturing capabilities within Australia and recognises biomaterials as a strength in research and a value add to enabling technologies for manufacturing.



Monash Industry Team Initiative Program (MITI) is an internship opportunity provided to Monash students in their penultimate year to work on an industry sponsored project in multidisciplinary teams

## MARCH 2018

As part of CCRM Australia's outreach to the sector, our executive team have travelled across the country to visit and network with the researchers at various institutes. One destination was the University of New South Wales, where technology evaluations activities occurred. These evaluations allow for researchers to leverage the CCRM network should their innovations align to the interest of CCRM, thus providing assistance to their commercialisation pathway.



UNSW Researchers present their innovations for a CCRM Australia Technology Evaluation

# CCRM AUSTRALIA HIGHLIGHTS

## APRIL 2018

The CCRM Australia Scientific Advisory Board was formalised with a group of 14 clinicians and researchers. The board was established to provide independent and objective advice to CCRM Australia's council and executive leaders by utilising their specialist knowledge to support the commercialisation of regenerative medicine in Australia.



## MAY 2018

CCRM Australia proudly introduced, along with the IMNIS (Industry Mentoring Network in STEM), Australia's first international mentoring program designed for Australian PhD students in regenerative medicine. The mentors and mentees interact through their monthly teleconference meetings. They are also provided an opportunity to meet face to face by supporting the mentee's attendance at a relevant regenerative medicine industry event with a CCRM Australia-IMNIS International Mentoring travel award.



*Dr Marguerite Evans-Galea, Director of IMNIS, welcomes attendees to the IMNIS National Launch held at KPMG Melbourne*

## JUNE 2018

CCRM Australia entered a partnership with Therapeutic Innovation Australia (TIA) to jointly develop an information system to curate data on the Australian regenerative medicine sector and to serve as both CCRM Australia's customer relationship management and project management platforms.



## JUNE 2018

CCRM Australia and the Victorian Government held an informal networking event coinciding with the ISSCR Conference. During this event, the BioNano Initiative was officially announced and Michael May, CEO of CCRM, announced their collaboration with Cell Therapies on regenerative medicine manufacturing.



*Canada announced their collaboration with Cell Therapies on Regenerative Medicine Manufacturing*

## JUNE 2018

CCRM Australia attends BIO International Convention in Boston, celebrating 25 years of Innovation for the convention. Hosted by the Biotechnology Innovation organization, the convention provides an opportunity to connect with global biotechnology and pharmaceutical leaders.



*Silvio Tiziani (CEO of CCRM Australia) with Australian Minister for Health Greg Hunt at the BIO International Convention*

## JULY 2018

CCRM Australia announced the formation of a platform providing a single touch point for comprehensive delivery of cell and gene therapy solutions. The Australian Alliance of Cell and Gene Therapy (AACGT) is a consortium of partners with complementary domain expertise throughout the cell and gene therapy value chain and offers an extensive network of partners to provide a complete service.



*The Partners of the Australia Alliance of Cell and Gene Therapy*

## JULY 2018

This year two Australian PhD students were able to attend Summer by Design, with CCRM Australia sponsoring their travel to the workshop for the second year running. The reflections from the participants of Workshop Placement as part of CCRM Australia's program have indicated the value that Summer by Design has in broadening their knowledge and professional development.



# CCRM AUSTRALIA IN FOCUS

## 1. END TO END ALLIANCE

### *Supporting the Cooperation Between Existing Regenerative Medicine Service Providers*

The newly formed Australian Alliance of Cell and Gene Therapy (AACGT) is ushering in a new era of networking for regenerative medicine companies. Partnering individual industry expertise as a consortium, the AACGT (formed by CCRM Australia), provides a single touchpoint for comprehensive delivery of cell and gene therapy solutions in Australia. By accessing this service, regenerative medicine companies can look forward to better cooperation and greater efficiency in the development of new therapies.

For CCRM Australia CEO, Silvio Tiziani, this alliance is the perfect example of how CCRM Australia is positioned to help accelerate and commercialise Australian regenerative medicine therapies. “By fostering greater collaboration between industry, clinicians and academics, we can harness this expansive reservoir of skills and expertise and offer a more comprehensive service” commented Silvio.

### **Services for an ‘End to End’ Solution**

By providing a suite of services, the AACGT supplies an ‘end to end’ solution (expertise support at all stages of pipeline development) for researchers and companies requiring specialised cell and gene therapy related services. By accessing the expertise of each alliance member, the AACGT will provide services that include:

- Pre-clinical proof of concept studies, product development expertise and pilot manufacturing.
- GMP process development, manufacturing and distribution for clinical and commercial uses.
- Clinical trial protocol development, IRB/Ethical approval, implementation, execution and;
- Commercialisation expertise.

For recent alliance member, Cell Therapies Pty Ltd (CTPL), this consortium provides a means of more efficient commercialisation of regenerative medicine therapies. “This alliance provides researchers with an efficient conduit into the complex machinery needed to bring pre-clinical projects out of the lab and into the clinic,” commented CEO of CTPL, Dr Dawn Driscoll. “Cell and gene therapies are being developed for a variety of medical conditions, including the most intractable diseases. Through the AACGT alliance, we will be able to speed up this long development process and bring these life saving therapies to patients more efficiently.”

### **The Alliance**

The alliance consists of current CCRM Australia members Cell Therapies Pty Ltd, the CRC for Cell Therapy Manufacturing and St Vincent’s Hospital Melbourne (along with CCRM Australia). For Dr Leanna Read, CEO and Chair of CRC for Cell Therapy Manufacturing, this alliance presents a huge advantage for Australian regenerative medicine.

“The challenge of bringing a therapy to market requires a broad array of skills, knowledge and infrastructure” commented Leanna, “The Australian regenerative medicine industry is small and the ability to leverage the skills and capabilities across the network of organisations within the AACGT alliance will have a tremendous impact on supporting emerging cell therapy companies in this region. The ability to more rapidly translate their products into the clinic will make these companies more globally competitive and position Australia as a leader in this maturing industry.”

### **Joining the Alliance**

Alliance partners encourage other Australian service providers with complementary expertise in the cell and gene therapy sector to contact us to discuss how your organisation can also contribute to the service offerings provided by the Australian Alliance of Cell and Gene Therapy (AACGT). With strong cooperation within regenerative medicine, we can look forward to a stronger future of Australian therapy development.



## 2. TRAINING PROGRAM (2017–2018)

### *Fostering the Development of Students and Early Career Researchers in Regenerative Medicine to become Industry Ready and Engaged with a Global Network.*

The CCRM Australia Training Program seeks to provide personal development opportunities for Australian PhD students and early career researchers in the regenerative medicine sector. The program allows participants to benefit by nurturing skills for greater professional readiness beyond academia. Our training also has impact for the growing local industry with participants incorporating their learnings gained from their experiences. This year's flagship programs were the International Workshop Placement at Summer by Design and the CCRM Australia's collaboration with The Industry Mentoring Network in STEM (IMNIS) on a Regenerative Medicine International Mentoring Program

The uniqueness of the CCRM Training program is that it offers an international perspective on commercialising science (workshop) and offers the experience of mentors who have worked in regenerative medicine on the global stage (mentoring).

### **International Workshop Placement**

Summer by Design is an international workshop hosted by the University of Toronto's Medicine by Design initiative in partnership with the Rotman School of Management. There is a focus on skill development in the areas of clinical translation and commercialisation of regenerative medicine with participants

from all over the world gathering together for the workshop. The program involves various activities for all attendees to network and share their knowledge as well as presentations to showcase each participant's home institute and their perspective on regenerative medicine.

Having previously participated in 2017 with Dr Hsern Ern Tan from the Ear Science Institute of Australia as our representative, CCRM Australia were again invited to send delegates this year. Sebastian Eggert from the Institute of Health and Biomedical Innovation at Queensland University of Technology and Jasmine Wilson from the University of Adelaide (whose research is supported by the CRC for Cell Therapy Manufacturing) were selected to attend for 2018.

*"My perspectives on the importance of collaboration have been reinforced by my experience at Summer by Design,"* said Tan on his reflection of the experience.

While Eggert, summarised the workshop with *"Summer by Design draws people from various areas around regenerative medicine applications. These people with the experts together in one workshop result in an inspiring time, leading to great discussions and very valuable insights in translational research and commercialisation in regenerative medicine."*

Post workshops, the CCRM Australian representatives all felt that their experiences were invaluable. They certainly will endeavour to incorporate into their current research the ideas generated, potential future collaborations and key learnings as well as helping to motivate others in the commercialisation pathway.



Students at the Medicine by Design Workshop Photo by Neil Ta

### International Mentoring Program

In collaboration with IMNIS, CCRM Australia was proud to launch Australia's first international mentoring program designed for Australian PhD students in regenerative medicine. The program offers PhD students a unique opportunity to be mentored by an internationally-recognised, executive industry leader working in the regenerative medicine sector. The mentors involved in the program come from across the globe including the UK, USA, Israel and Canada.

"This industry mentoring program provides an excellent networking opportunity that will assist in developing the next generation of regenerative medicine professionals," commented Dr Marguerite Evans-Galea, Executive Director of IMNIS. "With the mentors being part of leading regenerative medicine centres and organisations, we are excited for the launch of this initiative."

Five exceptionally qualified candidates from across Australia have been selected for the program. The mentors and mentees interact through their monthly teleconference meetings which will allow students to be informed about the regenerative medicine industry itself as well as potential professional careers. This program will enhance the professional development and knowledge base of early career researchers. The mentees are also provided an opportunity to meet face to face with their mentors through supporting their attendance to a relevant regenerative medicine industry event with a CCRM Australia-IMNIS International Mentoring travel award.

"We are determined to provide unique international opportunities to Australia's regenerative medicine sector," commented CCRM Australia's CEO Silvio Tiziani. "This is achieved through access to commercialisation expertise, funding sources and the very best technical expertise and/or facilities. The mentoring program is an important element of these objectives – ensuring that there is a pathway for Australian students to develop and progress in the sector."


Having received such positive feedback from our participants and showing the success of our current offerings, we are looking forward to new training opportunities for next year. CCRM Australia will continue its vision by being a facilitator in training the future workforce in regenerative medicine to have dynamic business leadership.



CCRM Australia and mentees at the IMNIS National Launch

# GOVERNANCE

## CCRM AUSTRALIA COMMITTEE AND NETWORKS STRUCTURE



## EXECUTIVE TEAM

### Chief Executive Officer

Silvio Tiziani

### Chief Operating Officer


Chih Wei Teng

### Project Officer

Erick Villaceran

### Executive Assistant and Events Coordinator

Heather Marriott



Front cover image: From Cells I See 2017 derivative of "Fight to the Death" by Jennifer Ma


*CCRM Australia accelerates the commercialisation of Australian regenerative medicine therapies and related technologies. We do this through engagement and fostering local and international collaboration between industry, clinicians and academia; thereby nurturing local regenerative medicine companies for the international market.*



#### **Contact details**

Address: 15 Innovation Walk, Monash University  
Clayton Campus, Clayton VIC 3800 Australia

 CCRM\_au ([twitter.com/CCRM\\_au](https://twitter.com/CCRM_au))

 CCRM Australia ([www.linkedin.com/company/ccrm-australia/](https://www.linkedin.com/company/ccrm-australia/))